Pharmacoeconomic analysis of drug supply of the military personnel with chronic bronchitis
Despite the superiority of bronchitis in the structure of respiratory diseases in the military personnel, its course develops with certain peculiarities due to the peculiarities of military service. Consequently, the optimization of the costs of providing the military personnel with medicines is becoming more and more of medical and social importance. Reasonable selection of medicines in the treatment of chronic bronchitis is the result of the choice of effective and safe drugs, considering the cost of the components for military health care.
Aim. To perform a pharmacoeconomic analysis of drug supply to the military personnel with chronic bronchitis.
Materials and methods. The materials of the study were a database of drugs registered in Ukraine, presented on the official website of the State Institution “State Expert Center” of the Ministry of Health of Ukraine. The study employed “cost – effectiveness” method, which allows comparing the cost of a particular treatment method and its effectiveness.
Results. The scheme of the pharmacoeconomic analysis method has been offered. According to the results of the previously formed list of drugs for the treatment of military personnel with chronic bronchitis, a further analysis of the proposed range of drugs is conducted using an expert survey. By calculating the efficacy ratio within each presented pharmacotherapeutic group, a 10-item list of the most optimal drugs for the treatment of chronic bronchitis has been compiled.
Conclusions. Pharmacoeconomic analysis of medical supply to the military personnel is a constructive solution in the process of identifying manufacturers as potential suppliers of medicines to cover the needs of the medical service of the Armed Forces of Ukraine. Based on the results of the pharmacoeconomic analysis of the drug supply to military personnel with chronic bronchitis, a recommended list of drugs for their treatment has been formed. However, this list can be expanded to include drugs with the highest efficacy – according to the expert assessment. In the future it may become the basis for inclusion of drugs in the clinical protocols of medical care and could be used for the development of cost standards for the relevant nosological forms, which will improve the efficiency and quality of treatment and will provide economic benefits.
Klyachkina, I. L. (2020). Khronicheskii bronkhit: farmakoterapevticheskii fokus na gipersensitivnyi komponent kashlya [Chronic bronchitis: pharmacotherapeutic focus on cough hypersensitivity component]. Consilium Medicum, 22(3), 46-54. [in Russian]. https://doi.org/10.26442/20751753.2020.3.200055
Stefaniuk, M. F. (1999). Morfofunktsionalnyi stan bronkhiv, zminy zahalnoho imunitetu ta nespetsyfichnoho klitynnoho zakhystu lehen pry povtornykh bronkhopnevmoniiakh u viiskovosluzhbovtsiv strokovoi sluzhby (Avtoref. dys... kand. med. nauk: 14.01.27) [Morphofunctional condition of the bronchi, changes in general immunity and nonspecific cellular protection of the lungs in recurrent bronchopneumonia in conscripts (Extended abstract of candidate’s thesis)]. Instytut ftyziatrii i pulmonolohii im. F. H. Yanovskoho. Kyiv. [in Ukrainian].
Derzhavnyi reiestr likarskykh zasobiv Ukrainy [State register of medicines of Ukraine]. [in Ukrainian]. http://www.drlz.kiev.ua
Kryvoviaz, O. V. (2016). Ekspertna otsinka likarskykh zasobiv hrupy S01E "Protyhlaukomni preparaty ta miotyky" [Expert evaluation of medicines from S01E pharmaceutical group "Antiglaucoma medicines and miotics"]. Farmatsevtychnyi chasopys, (3), 32-38. [in Ukrainian]. https://doi.org/10.11603/2312-0967.2016.3.6824
Kukhtenko, O. S., Nazarkina, V. M., & Gladukh, Y. V. (2017). Farmakoekonomichna otsinka dostupnosti likarskykh zasobiv dlia likuvannia zakhvoriuvan dykhalnykh shliakhiv [Pharmacoeconomic assessment of the availability of medicines for the treatment of respiratory diseases]. Farmatsevtychnyi chasopys, (3), 105-111. [in Ukrainian]. https://doi.org/10.11603/2312-0967.2017.3.8114
Matiashova, N. O., & Gerasymova O. O. (2019). Farmakoekonomichnyi analiz likarskykh preparativ, yaki vplyvaiut na strukturu ta mineralizatsiiu kistok [The pharmacoeconomic analysis of medicines affecting the bone structure and mineralization]. Klinichna farmatsiia, 23(1), 56-61. [in Ukrainian]. https://doi.org/10.24959/cphj.19.1481
Solovyov, S. O., & Dzyublyk, I. V. (2016). Farmakoekonomichnyi analiz stratehii diahnostyky hostrykh virusnykh infektsii: operatsiini kharakterystyky, metody ta pryklad otsinky [Pharmacoeconomic analysis of diagnosis strategies of acute viral infections: operating characteristics, methods of assessment and case study]. Infektsiini khvoroby, (1), 62-72. [in Ukrainian]. https://doi.org/10.11603/1681-2727.2016.1.5963
Kompendium. Likarski preparaty [Compendium. Medicines]. [in Ukrainian]. http://compendium.com.ua
Kramarov, S. O., & Grechukha, Ye. O. (2019). Aspekty likuvannia infektsii nyzhnikh dykhalnykh shliakhiv z pohliadu klinichnykh nastanov riznykh krain (bronkhiolit, bronkhit, pozahospitalna pnevmoniia) [Aspects of treatment of lower respiratory tract infections in terms of clinical guidelines of different countries (bronchiolitis, bronchitis, community-acquired pneumonia)]. Aktualna infektolohiia, 7(4), 181-188. [in Ukrainian]. https://doi.org/10.22141/2312-413x.7.4.2019.178878
Matyukha, L. P., Titova, T. A., & Tish, O. B. (2020). Pidkhody do likuvannia kashliu pry hostromu bronkhiti v ambulatornykh umovakh [Approaches to the treatment of cough in acute bronchitis in an outpatient setting]. Simeina medytsyna, (3), 67-74. [in Ukrainian].
Kotvitska, A., & Korobova, E. (2017). Naukove obgruntuvannia modeli rozrobky rekomendovanoho pereliku likarskykh zasobiv dlia farmakoterapii hostroho bronkhitu u ditei rannoho viku [Scientific substantiation of the model of the drugs’ recommended list development for pharmacotherapy of acute bronchitis in children of early age]. ScienceRise: Pharmaceutical Science. (4), 8-14. [in Ukrainian]. https://doi.org/10.15587/2519-4852.2017.108325
Kukhtenko, O. S., Gladukh, Ie. V., & Simonian, L. S. (2017). Analiz vitchyznianoho rynku likarskykh zasobiv dlia likuvannia zapalnykh zakhvoriuvan dykhalnykh shliakhiv [Domestic market analysis of medicinal products for treatment of inflammatory respiratory diseases]. Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, (4), 42-49. [in Ukrainian]. https://doi.org/10.24959/uekj.17.35
Kramarov, S. O., & Zakordonets, L. V. (2018). Pidkhody do likuvannia zakhvoriuvan nyzhnikh dykhalnykh shliakhiv: vybir antybakterialnoho preparatu z urakhuvanniam mizhnarodnykh rekomendatsii [Approaches to the treatment of diseases of the lower respiratory tract: choice of antibacterial preparation taking into account international recommendations]. Aktualna infektolohiia, 6(6), 314-319. [in Ukrainian].
Stadnytska, N. Ye., Мylyanych, A. O., Maltyz, І. S., Fito, I. V., Fedoryshyn, O. M., Komar, A. V., & Novikov, V. P. (2020). Asortyment likarskykh preparativ dlia likuvannia obstruktyvnykh zakhvoriuvan dykhalnykh shliakhiv, predstavlenykh na rynku Ukrainy [Range of medical products for treatment of obstructive respiratory diseases, presented on the market of Ukraine]. Farmatsevtychnyi chasopys, (1), 59-65. [in Ukrainian]. https://doi.org/10.11603/2312-0967.2020.1.10971
Petrukhnov, A. D. (2020). Kompleksna fizychna reabilitatsiia studentiv, khvorykh na khronichnyi bronkhit u period rekonvalestsentsii [Physical rehabilitation of students with chronic bronchitis during convalescence (Candidate’s thesis)]. Kharkiv State Academy of Physical Culture. Kharkiv. [in Ukrainian].
Wilson, R., Jones, P., Schaberg, T., Arvis, P., Duprat-Lomon, I., Sagnier, P. P., & MOSAIC Study Group (2006). Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax, 61(4), 337-342. https://doi.org/10.1136/thx.2005.045930
Chuchalin, A., Zakharova, M., Dokic, D., Tokić, M., Marschall, H. P., & Petri, T. (2013). Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). BMC pulmonary medicine, 13, 5. https://doi.org/10.1186/1471-2466-13-5
Wilson, R., Anzueto, A., Miravitlles, M., Arvis, P., Alder, J., Haverstock, D., Trajanovic, M., & Sethi, S. (2012). Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. The European respiratory journal, 40(1), 17-27. https://doi.org/10.1183/09031936.00090311
Mejza, F., Gnatiuc, L., Buist, A. S., Vollmer, W. M., Lamprecht, B., Obaseki, D. O., Nastalek, P., Nizankowska-Mogilnicka, E., Burney, P., BOLD collaborators, & BOLD study collaborators (2017). Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study. The European respiratory journal, 50(5), 1700621. https://doi.org/10.1183/13993003.00621-2017
Perotin, J. M., Launois, C., Dewolf, M., Dumazet, A., Dury, S., Lebargy, F., Dormoy, V., & Deslee, G. (2018). Managing patients with chronic cough: challenges and solutions. Therapeutics and clinical risk management, 14, 1041-1051. https://doi.org/10.2147/TCRM.S136036
Arkhipov, V., Arkhipova, D., Miravitlles, M., Lazarev, A., & Stukalina, E. (2017). Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. International journal of chronic obstructive pulmonary disease, 12, 3255-3262. https://doi.org/10.2147/COPD.S142997
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)